The charts on this page feature a breakdown of the total annual pay for the top executives at Protalix BioTherapeutics, Inc. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Protalix BioTherapeutics, Inc. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Protalix BioTherapeutics, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Yossi Maimon CPA
Vice President, Chief Financial Officer
Total Cash $422,649 Equity $59,089 Other $75,813 Total Compensation $557,551
Yoseph Shaaltiel Ph.D.
Executive Vice President, Research and Development
Total Cash $288,719 Equity $60,575 Other $84,148 Total Compensation $433,442
Einat Brill Almon Ph.D.
Senior Vice President, Product Development
Total Cash $369,583 Equity $59,089 Other $75,369 Total Compensation $504,041
Moshe Manor
President and Chief Executive Officer
Total Cash $506,551 Equity $106,820 Other $104,283 Total Compensation $717,654
Yaron Naos
Senior Vice President, Operations
Total Cash $218,058 Equity $40,878 Other $80,338 Total Compensation $339,274
For its 2018 fiscal year, Protalix BioTherapeutics, Inc., listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Moshe Manor CEO Pay $717,654 Median Employee Pay $47,782 CEO Pay Ratio 15:1
For its 2018 fiscal year, Protalix BioTherapeutics, Inc., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Aharon Schwartz, Ph.D. Total Cash $65,556
Amos Bar Shalev Total Cash $80,000
David Granot Total Cash $19,758
Shlomo Yanai Total Cash $200,000
Yodfat Harel Buchris Total Cash $20,000
Zeev Bronfeld Total Cash $80,000

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.